Starpharma Holdings Ltd is an Australia-based company engaged in the research, development, and commercialization of dendrimer products for pharmaceutical, life science, and other applications. It focuses on the development of VivaGel for the management and prevention of bacterial vaginosis and as a condom coating, and VIRALEZE, an antiviral nasal spray.
1997
40
LTM Revenue $5.3M
LTM EBITDA -$4.5M
$62.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of September 2025, Starpharma reported last 12-month revenue of $5.3M and EBITDA of -$4.5M.
In the same period, Starpharma generated $4.2M in LTM gross profit.
See Starpharma valuation multiples based on analyst estimatesIn the most recent fiscal year, Starpharma reported revenue of $3.2M and EBITDA of -$7.1M.
Starpharma expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Starpharma valuation multiples based on analyst estimatesLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue | $5.3M | XXX | $3.2M | XXX | XXX | XXX |
Gross Profit | $4.2M | XXX | $2.4M | XXX | XXX | XXX |
Gross Margin | 79% | XXX | 75% | XXX | XXX | XXX |
EBITDA | -$4.5M | XXX | -$7.1M | XXX | XXX | XXX |
EBITDA Margin | -85% | XXX | -222% | XXX | XXX | XXX |
EBIT | n/a | XXX | -$7.8M | XXX | XXX | XXX |
EBIT Margin | n/a | XXX | -244% | XXX | XXX | XXX |
Net Profit | n/a | XXX | -$6.5M | XXX | XXX | XXX |
Net Margin | n/a | XXX | -203% | XXX | XXX | XXX |
Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Starpharma has current market cap of AUD 109M (or $70.8M), and EV of AUD 95.7M (or $62.3M).
As of October 17, 2025, Starpharma's stock price is AUD 0 (or $0).
See Starpharma trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$62.3M | $70.8M | XXX | XXX | XXX | XXX | $-0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialStarpharma's trades at 14.5x EV/Revenue multiple, and -9.3x EV/EBITDA.
See valuation multiples for Starpharma and 15K+ public compsAs of October 17, 2025, Starpharma has market cap of $70.8M and EV of $62.3M.
Equity research analysts estimate Starpharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Starpharma's P/E ratio is not available.
LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $70.8M | XXX | $70.8M | XXX | XXX | XXX |
EV (current) | $62.3M | XXX | $62.3M | XXX | XXX | XXX |
EV/Revenue | 11.7x | XXX | 14.5x | XXX | XXX | XXX |
EV/EBITDA | -13.8x | XXX | -9.3x | XXX | XXX | XXX |
EV/EBIT | n/a | XXX | -8.4x | XXX | XXX | XXX |
EV/Gross Profit | 14.9x | XXX | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | -12.0x | XXX | XXX | XXX |
EV/FCF | n/a | XXX | -13.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStarpharma's last 12 month revenue growth is 124%
Starpharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Starpharma's rule of 40 is -32% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Starpharma's rule of X is 224% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Starpharma and other 15K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | 124% | XXX | 74% | XXX | XXX | XXX |
EBITDA Margin | -85% | XXX | -156% | XXX | XXX | XXX |
EBITDA Growth | -86% | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | -32% | XXX | -32% | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | 224% | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 170% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 319% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Starpharma acquired XXX companies to date.
Last acquisition by Starpharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Starpharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free TrialWhen was Starpharma founded? | Starpharma was founded in 1997. |
Where is Starpharma headquartered? | Starpharma is headquartered in Australia. |
How many employees does Starpharma have? | As of today, Starpharma has 40 employees. |
Is Starpharma publicy listed? | Yes, Starpharma is a public company listed on ASX. |
What is the stock symbol of Starpharma? | Starpharma trades under SPL ticker. |
When did Starpharma go public? | Starpharma went public in 2000. |
Who are competitors of Starpharma? | Similar companies to Starpharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
What is the current market cap of Starpharma? | Starpharma's current market cap is $70.8M |
What is the current revenue of Starpharma? | Starpharma's last 12 months revenue is $5.3M. |
What is the current revenue growth of Starpharma? | Starpharma revenue growth (NTM/LTM) is 124%. |
What is the current EV/Revenue multiple of Starpharma? | Current revenue multiple of Starpharma is 11.7x. |
Is Starpharma profitable? | Yes, Starpharma is EBITDA-positive (as of the last 12 months). |
What is the current EBITDA of Starpharma? | Starpharma's last 12 months EBITDA is -$4.5M. |
What is Starpharma's EBITDA margin? | Starpharma's last 12 months EBITDA margin is -85%. |
What is the current EV/EBITDA multiple of Starpharma? | Current EBITDA multiple of Starpharma is -13.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.